Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus

被引:65
作者
Arriens, Cristina [1 ]
Hynan, Linda S. [2 ,3 ]
Lerman, Robert H. [4 ]
Karp, David R. [1 ]
Mohan, Chandra [5 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Rheumat Dis, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Clin Sci Biostat, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA
[4] Metagenics Inc, Funct Med Res Ctr, Gig Harbor, WA USA
[5] Univ Houston, Dept Biomed Engn, Houston, TX USA
来源
NUTRITION JOURNAL | 2015年 / 14卷
关键词
ATTENUATES KIDNEY-DISEASE; FATTY-ACID-COMPOSITION; DIETARY SUPPLEMENTATION; MULTIPLE-SCLEROSIS; MOUSE MODEL; OMEGA-3; NEPHRITIS; INFLAMMATION; SLE; CLASSIFICATION;
D O I
10.1186/s12937-015-0068-2
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Introduction: A recent metabolomic screen of sera from patients with Systemic Lupus Erythematosus (SLE) found reduction of antioxidants and substrates for energy generation. These metabolic alterations may underlie one of the most common features of SLE - fatigue. The metabolomic studies also noted reduced omega-3 fatty acids, which are powerful anti- oxidants. This deficiency may be causally related to oxidative stress, inflammation, disease activity, and fatigue in SLE. Supplementation of omega-3 fatty acids using fish oil in SLE has been shown to reduce oxidative stress in other studies. The objective of this study is to evaluate the effect of fish oil supplementation on clinical measures of fatigue, quality of life, and disease activity as part of a randomized clinical trial. Methods: Fifty SLE patients recruited in outpatient clinics were randomized 1:1 to fish oil supplementation or olive oil placebo, and blinded to their treatment group. At baseline and after 6 months of treatment, RAND Short Form-36 (RAND SF-36), Fatigue Severity Scale (FSS), SLE Disease Activity Index (SLEDAI), and Physician Global Assessment (PGA) were completed; serum was also collected for soluble mediator analysis. Results: Thirty-two patients completed the study. PGA improved significantly in the fish oil group compared with the placebo group (p = 0.015). The RAND SF-36 Energy/fatigue and Emotional well-being scores demonstrated improvement trends (p = 0.092 and 0.070). No clear difference was seen in FSS and SLEDAI (p = 0.350 and p = 0.417). Erythrocyte sedimentation rate and serum IL-12 were reduced (p = 0.008 and p = 0.058); while serum IL-13 was increased by fish oil supplementation (p = 0.033). Conclusions: In this randomized, placebo-controlled 6-month trial, SLE patients randomized to fish oil supplementation demonstrated improvement in their PGA, RAND SF-36, and some circulating inflammatory markers.
引用
收藏
页数:11
相关论文
共 42 条
  • [1] Alterations in Circulating Fatty Acid Composition in Patients with Systemic Lupus Erythematosus: A Pilot Study
    Aghdassi, Elaheh
    Ma, David W. L.
    Morrison, Stacey
    Hillyer, Lynn M.
    Clarke, Shannon
    Gladman, Dafna D.
    Urowitz, Murray B.
    Fortin, Paul R.
    [J]. JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2011, 35 (02) : 198 - 208
  • [2] Measurement of fatigue in systemic lupus erythematosus: A systematic review
    不详
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (08): : 1348 - 1357
  • [3] Intention to treat analysis, compliance, drop-outs and how to deal with missing data in clinical research: a review
    Armijo-Olivo, Susan
    Warren, Sharon
    Magee, David
    [J]. PHYSICAL THERAPY REVIEWS, 2009, 14 (01) : 36 - 49
  • [4] Arriens Cristina, 2013, Int J Clin Rheumtol, V8, P671
  • [5] Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus
    Bello, Kayode J.
    Fang, Hong
    Fazeli, Parastoo
    Bolad, Waleed
    Corretti, Mary
    Magder, Laurence S.
    Petri, Michelle
    [J]. RHEUMATOLOGY INTERNATIONAL, 2013, 33 (11) : 2789 - 2796
  • [6] DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS
    BOMBARDIER, C
    GLADMAN, DD
    UROWITZ, MB
    CARON, D
    CHANG, CH
    [J]. ARTHRITIS AND RHEUMATISM, 1992, 35 (06): : 630 - 640
  • [7] The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus:: A randomized trial
    Buyon, JP
    Petri, MA
    Kim, MY
    Kalunian, KC
    Grossman, J
    Hahn, BH
    Merrill, JT
    Sammaritano, L
    Lockshin, M
    Alarcón, GS
    Manzi, S
    Belmont, HM
    Askanase, AD
    Sigler, L
    Dooley, MA
    Von Feldt, J
    McCune, WJ
    Friedman, A
    Wachs, J
    Cronin, M
    Hearth-Holmes, M
    Tan, M
    Licciardi, F
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 142 (12) : 953 - 962
  • [8] OMEGA-3 FATTY-ACID DIETARY SUPPLEMENTATION IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    CLARK, WF
    PARBTANI, A
    HUFF, MW
    REID, B
    HOLUB, BJ
    FALARDEAU, P
    [J]. KIDNEY INTERNATIONAL, 1989, 36 (04) : 653 - 660
  • [9] FISH-OIL IN LUPUS NEPHRITIS - CLINICAL FINDINGS AND METHODOLOGICAL IMPLICATIONS
    CLARK, WF
    PARBTANI, A
    NAYLOR, CD
    LEVINTON, CM
    MUIRHEAD, N
    SPANNER, E
    HUFF, MW
    PHILBRICK, DJ
    HOLUB, BJ
    [J]. KIDNEY INTERNATIONAL, 1993, 44 (01) : 75 - 86
  • [10] Acquired resistance to Listeria monocytogenes during a secondary infection in a murine model fed dietary lipids
    Cruz-Chamorro, Lidia
    Puertollano, Elena
    Alvarez de Cienfuegos, Gerardo
    Puertollano, Maria A.
    de Pablo, Manuel A.
    [J]. NUTRITION, 2011, 27 (10) : 1053 - 1060